kiomedine

Kiomedine is a **novel, animal-free, chitosan-based intraarticular injectable** used as a synovial fluid viscosupplementation implant for the symptomatic treatment of knee osteoarthritis. Its primary component is Kiomedine CM Chitosan, a proprietary, highly purified carboxymethyl chitosan derivative sourced from Agaricus bisporus (edible mushroom)[3][5]. The drug works through a dual mechanism of action—**enhancing joint lubrication and scavenging free radicals**—which reduces joint friction and protects endogenous hyaluronic acid in the synovial fluid, thereby slowing oxidative degradation and symptom progression[1][3][5]. Kiomedine is supplied as a single-use, sterile, pre-filled syringe for intraarticular injection, providing up to 6–12 months of symptom relief in knee osteoarthritis patients[1][3][4][5]. Developed and manufactured by KiOmed Pharma in Belgium, Kiomedine represents a new generation viscosupplementation device, targeting patients unresponsive to established treatments and providing a cost-saving alternative to total knee replacement surgery[4].

Brand names

KiomedineVSone

Other names

kiomedinekiomedine cm-chitosan